![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Homepage | Lupus Science & Medicine
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...
Homepage | Lupus Science & Medicine
A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.
Characteristics and clinical outcomes of patients with systemic …
10 小时之前 · Introduction Anifrolumab (Saphnelo) is approved for adult patients with moderate-severe systemic lupus erythematosus (SLE). Considering its commercialisation in Spain in 2023, observational studies describing the use of anifrolumab in routine clinical practice are limited. The aim of the AZAHAR study is to describe the characteristics and clinical outcomes of patients with SLE who initiated ...
Long-term safety and efficacy of the combination of belimumab …
10 小时之前 · Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are currently lacking. To address this, we analysed outcomes of patients with severe treatment-refractory SLE who previously participated in the phase II Synbiose Study, with a particular focus on ...
Rare and common single nucleotide variants in childhood-onset …
1 天前 · Materials and methods Targeted sequencing of 1832 gene regions, including coding regions of 31 genes associated with monogenic SLE, was performed in 958 patients with SLE and 1026 healthy individuals. A total of 116 patients with SLE had disease onset before the age of 18 (cSLE). An SLE common variant PRS was created from 37 SLE genome-wide association study single nucleotide variants (SNVs).
Time trends of variability in disease activity in systemic lupus ...
10 小时之前 · Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in SLE disease activity over time.Methods We analysed data from 2930 patients with SLE across 13 countries, collected over 38 754 clinic visits between 2013 and 2020. Clinic visit records were ...
Association of race and ethnicity with mortality in adults with SLE: …
1 天前 · Objectives Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. SLE is a disease with higher incidence in Asian, Black, Hispanic and Indigenous populations than in White populations. SLE is associated with premature mortality, but it is unclear if ethnicity impacts on health outcomes as studies are frequently underpowered. We aimed to describe the ...
About | Lupus Science & Medicine - Lupus Science & …
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. The journal publishes research on lupus from fields including, but not limited to: rheumatology, dermatology, …
Postmarketing safety evaluation of belimumab: a …
2025年1月8日 · Objective The present study aimed to provide a comprehensive evaluation of the postmarketing safety of belimumab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods Adverse event (AE) reports in the FAERS database from January 2021 to December 2023 were extracted to perform the disproportionality analysis by calculating the reporting OR. The ...
Characterisation and outcomes of different subsets of low disease ...
2024年9月17日 · Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity.Methods Patients with SLE enrolled in ...